hotspot -WSS

hotspot

author：entertainment 2025-09-03 12:03:38 - browse：952

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Obesity drugs seen as possible treatment for liver disease MASH

focus

WSS

Eight reasons why you should get an updated Covid vaccine

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Readout LOUD podcast: Merger Mondays, Ozempic panic

How clinical AI models' predictive power can degrade over time

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

hotspot

hotspot

entertainment

In Memoriam: Notable people who died in 2023

Female surgeons have lower rates of long

Psychedelics group wrestles with new pharma identity

In utero gene editing: an explainer

At least 13 dead in Texas as scorching temps continue

What's changing in Medicare's open enrollment this year?

Hollywood unions extend contract negotiations for actors

Humana CEO Bruce Broussard to step down in 2024

The cancer drug shortage isn’t new — and neither are the solutions

Massive project maps cells in human brain in unprecedented detail

hotspot

Medicare to cover more brain scans related to Alzheimer’s drugs

How should state employee insurance handle Wegovy?

European regulators consider appeal over Amylyx ALS drug

NIH study of ME/CFS points to clear biological hallmarks

In utero gene editing: an explainer

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

hotspot

focus

explore

knowledge